Filana Therapeutics (FLNA) investor relations material

Executive summary

• Focus shifted to developing simufilam for TSC-related epilepsy after discontinuing Alzheimer’s disease trials in 2025 and rebranding to Filana Therapeutics.

• Simufilam IND for TSC-related epilepsy is on full clinical hold pending additional data and protocol modifications requested by FDA; company is actively addressing these requirements.

• Positive preclinical results in TSC mouse models published and presented at major scientific forums; clinical trial initiation delayed beyond H1 2026.

• Exclusive worldwide license agreement with Yale for simufilam in TSC-related epilepsy signed in February 2025.

Financial highlights

• Net loss for Q1 2026 was $10.3 million ($0.21 per share), a 56% improvement from $23.4 million ($0.48 per share) in Q1 2025.

• Research and development expenses decreased 67% year-over-year to $4.5 million due to the phase-out of Alzheimer’s program.

• General and administrative expenses fell 39% year-over-year to $6.6 million, mainly due to lower legal loss contingencies.

• Cash and cash equivalents were $86.6 million as of March 31, 2026, down from $95.5 million at year-end 2025.

• Net cash used in operations was $8.9 million for Q1 2026; first-half 2026 operational cash use expected at $14–17 million, plus a $31.25 million litigation settlement payment.

Outlook and guidance

• Research and development expenses expected to remain significantly lower in the near term as focus shifts to TSC-related epilepsy.

• Cash at June 30, 2026, projected between $47–50 million.

• Company believes current cash position is sufficient to fund operations for at least the next 12 months.

• Initiation of clinical trial for simufilam in TSC-related epilepsy depends on FDA feedback and additional data submission.